News
-
-
COMMUNIQUÉ DE PRESSE
Ad hoc announcement pursuant to Art. 53 LR: Jungfraubahn Holding AG - The Jungfrau Railway Group achieves record profit in the first half of the year
Jungfraubahn Holding AG reports record profit in the first half of 2025, driven by increased transport income. New CEO and sustainability efforts highlighted -
COMMUNIQUÉ DE PRESSE
Helvetica Swiss Living Fund convainc au premier semestre 2025 par un résultat global nettement plus élevé, un revenu net par part en hausse et un solide rendement des placements
Helvetica Swiss Living Fund affiche un résultat semestriel 2025 nettement plus élevé: revenu net par part en hausse, solide rendement des placements. Attractivité des sites suburbains -
COMMUNIQUÉ DE PRESSE
Helvetica Swiss Commercial Fund impresses in the first half of 2025 with strong net income, performance above the benchmark and successful fund merger
Helvetica Swiss Commercial Fund achieves strong net income and performance above benchmark in first half of 2025 with a successful fund merger. Details in HSC Fund's 2025 Half-Year Report -
COMMUNIQUÉ DE PRESSE
Helvetica Swiss Living Fund impresses in the first half of 2025 with significantly higher total profit, increased net income per unit and strong return on investment
Helvetica Swiss Living Fund reports strong financial performance in the first half of 2025, with increased net income per unit and 2.94% return on investment -
COMMUNIQUÉ DE PRESSE
Helvetica Swiss Commercial Fund convainc au premier semestre 2025 par un solide revenu net, une performance supérieure à l’indice de référence et une fusion réussie des fonds
Le Helvetica Swiss Commercial Fund affiche un solide revenu net et une performance supérieure au premier semestre 2025, avec fusion réussie des fonds -
COMMUNIQUÉ DE PRESSE
Pleasing half-year results for Cham Swiss Properties
Cham Swiss Properties AG reports pleasing half-year results, with net income from revaluation boosting consolidated profit to CHF 144.0 million and equity ratio at 61.1%. Operating result excluding revaluation is CHF 39.0 million -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Heidelberg Pharma's partner Telix Pharmaceuticals faces delays in TLX250-CDx FDA approval. USD 70 million payment from HealthCare Royalty postponed. Current cash reach until Q1 2026 -
-
